KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Aquestive Therapeutics (AQST) Shares Outstanding (Diluted Average) (2020 - 2025)

Historic Shares Outstanding (Diluted Average) for Aquestive Therapeutics (AQST) over the last 6 years, with Q3 2025 value amounting to $110.6 million.

  • Aquestive Therapeutics' Shares Outstanding (Diluted Average) rose 2141.18% to $110.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $110.6 million, marking a year-over-year increase of 2141.18%. This contributed to the annual value of $86.7 million for FY2024, which is 4158.03% up from last year.
  • As of Q3 2025, Aquestive Therapeutics' Shares Outstanding (Diluted Average) stood at $110.6 million, which was up 2141.18% from $99.3 million recorded in Q2 2025.
  • In the past 5 years, Aquestive Therapeutics' Shares Outstanding (Diluted Average) registered a high of $110.6 million during Q3 2025, and its lowest value of $35.6 million during Q1 2021.
  • Moreover, its 5-year median value for Shares Outstanding (Diluted Average) was $61.3 million (2023), whereas its average is $65.5 million.
  • Its Shares Outstanding (Diluted Average) has fluctuated over the past 5 years, first skyrocketed by 7796.08% in 2023, then dropped by 24.15% in 2024.
  • Over the past 5 years, Aquestive Therapeutics' Shares Outstanding (Diluted Average) (Quarter) stood at $38.1 million in 2021, then rose by 27.99% to $48.7 million in 2022, then grew by 25.69% to $61.3 million in 2023, then soared by 41.58% to $86.7 million in 2024, then increased by 27.51% to $110.6 million in 2025.
  • Its last three reported values are $110.6 million in Q3 2025, $99.3 million for Q2 2025, and $95.5 million during Q1 2025.